Targeting the human transferrin receptor 1 (TfR) to deliver therapeutic oligonucleotides is a promising strategy for treating liver and pancreatic cancers, due to the overexpression of TfR on the surface of cancer cells [22], including HCC [23] and metastatic PDAC [24] cells. The gene discussed is TFRC; the disease is hepatocellular carcinoma.